Electrolyte and Blood Pressure最新文献

{"title":"A Case of Cystinuria With Compound Heterozygous Mutations Both in <i>SLC3A1</i> and <i>SLC7A9</i> Genes.","authors":"Sang Heon Suh, Su Hyun Song, Hong Sang Choi, Chang Seong Kim, Eun Hui Bae, Soo Wan Kim, Seong Kwon Ma","doi":"10.5049/EBP.2025.23.e2","DOIUrl":"10.5049/EBP.2025.23.e2","url":null,"abstract":"<p><p>Cystinuria is an autosomal recessively inherited genetic disorder, and is typically classified into type A, caused by mutations in <i>SLC3A1</i>, or type B, caused by mutations in <i>SLC7A9</i>. While the predominance of the genotypes varies among countries, due to lack of a large scale cohort, the characterization of mutations in <i>SLC3A1</i> or <i>SLC7A9</i> is still limited in East Asia. A 61-year-old male patient admitted to the department of nephrology, with a chief complaint of fever, chillness and left flank pain for a week. The patient had a past history of recurrent urolithiasis, with a frequency of at least 1 to 2 times a year. Computed tomography visualized 1 cm-sized stone at distal ureter, which was removed by retrograde ureteroscopy. The stone analysis documented 100% of cystine, indicating an underlying genetic disorder, cystinuria. Whole genome sequencing from peripheral blood unveiled 3 heterozygous missense mutations in coding exons of <i>SLC3A1</i> gene, and 2 heterozygous missense mutations in coding exons of <i>SLC7A9</i> gene. We here report a case of cystinuria with compound heterozygous mutations both in <i>SLC3A1</i> and <i>SLC7A9</i> genes, with a total of 5 mutant alleles in a patient.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"23 1","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytotoxic Lesions of the Corpus Callosum Preceding Osmotic Demyelination Syndrome in Hypernatremia and Hyperosmolar Hyperglycemic State: A Case Report.","authors":"Hye Jin Park, Su Hyun Song, Sang Heon Suh, Hong Sang Choi, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim, Chang Seong Kim","doi":"10.5049/EBP.2025.23.e3","DOIUrl":"10.5049/EBP.2025.23.e3","url":null,"abstract":"<p><p>Osmotic demyelination syndrome (ODS) is a rare neurological disorder associated with osmotic imbalances. Traditionally, ODS has been known to occur following the rapid correction of hyponatremia; however, ODS has also been reported concerning hypernatremia and hyperglycemia. Cytotoxic lesions of the corpus callosum (CLOCC), identified using transient magnetic resonance imaging, can arise from various causes, including drugs, vascular diseases, infections, and metabolic disturbances such as electrolyte imbalances and dysglycemia. The simultaneous occurrence of ODS and CLOCC is extremely rare. Here, we report a case whereby a 57-year-old male initially developed CLOCC via severe hypernatremia and hyperosmolar hyperglycemic state (HHS) was also subsequently identified with ODS. Physicians should know CLOCC may be an early radiologic finding in ODS associated with severe hypernatremia and HHS. Therefore, proactive brain imaging should be considered in these patients to facilitate the early detection of neurological complications.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"23 1","pages":"11-16"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Safety of Telminuvo, a Single Pill Combination of Telmisartan and S-amlodipine, in Korean Hypertensive Patients: A Multicenter, Retrospective Cohort Study.","authors":"Hongran Moon, Sohyun Bae, Donghwan Yun, Hyung-Kwan Kim, Sung Uk Kwon, Min Su Hyon, Seung Seok Han","doi":"10.5049/EBP.2025.23.e1","DOIUrl":"10.5049/EBP.2025.23.e1","url":null,"abstract":"<p><strong>Background: </strong>Effective blood pressure (BP) control is vital for preventing target organ damage, and combination therapy offers added benefits when single-agent treatment is insufficient. This cohort study examined whether Telminuvo, a single-pill combination of telmisartan and S-amlodipine, effectively maintains kidney function as a target organ in a large cohort of Korean patients.</p><p><strong>Methods: </strong>A total of 4,934 patients from 30 hospitals were treated with Telminuvo for over six months, with BP, estimated glomerular filtration rate (eGFR), electrolyte levels, and adverse events monitored throughout the study period.</p><p><strong>Results: </strong>Among the participants, 1,463 (29.7%) used Telminuvo for less than 1 year, while the remainder used it for longer. At baseline, the systolic and diastolic BP averaged 140.2 ± 18.4 mmHg and 82.1 ± 13.4 mmHg, respectively, which significantly decreased to approximately 130 and 75 mmHg after the initiation of treatment. The baseline eGFR of 79.3 mL/min/1.73 m² remained stable over three years, regardless of the initial eGFR levels. Within the first six months, acute kidney injury (defined as either a ≥ 0.3 mg/dL increase in serum creatinine or a ≥ 50% increase from baseline) occurred in 6.6% of patients, while hyperkalemia (defined as serum potassium levels > 5.5 mmol/L) was observed in 3.2% of patients.</p><p><strong>Conclusion: </strong>This cohort study demonstrates that Telminuvo effectively reduces blood pressure without compromising kidney function. Furthermore, the findings provide additional insights into drug-related adverse events, which will be valuable for clinicians in the real-world prescribing of Telminuvo.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"23 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond.","authors":"Sangyub Han, Sejoong Kim","doi":"10.5049/EBP.2024.22.2.21","DOIUrl":"https://doi.org/10.5049/EBP.2024.22.2.21","url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is a prevalent and complex disease among patients with diabetes in Korea, requiring comprehensive treatment strategies. Traditional management strategies targeting blood pressure, blood sugar, lipid, and lifestyles are foundational approaches of DKD treatment, each of them still holding importance in current paradigms. The four pillars, renin-angiotensin system(RAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and non-steroidal mineralocorticoid receptor antagonists (nsMRA) can enhance DKD treatment. Expanding beyond these pillars with future-oriented pillars including precision medicine, digital health, gut health, anti-inflammatory/fibrotic agents, psychosocial/behavioral health, and regenerative medicine can further advance DKD treatment strategies, offering a more cohesive framework which shifts a disease-centered approach to a patient-centered approach.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"22 2","pages":"21-28"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management Strategies for Potassium Levels During Non-steroidal Mineralocorticoid Receptor Antagonist Therapy: A Comprehensive Review.","authors":"Hyung Eun Son","doi":"10.5049/EBP.2024.22.2.29","DOIUrl":"https://doi.org/10.5049/EBP.2024.22.2.29","url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD). Recent advancements highlight the role of finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), in DKD management. Studies like FIDELIO-DKD, FIGARO-DKD, and FIDELITY have demonstrated finerenone's efficacy in reducing CKD progression and cardiovascular risks in DKD patients. Trials reveal higher incidence of hyperkalemia in finerenone groups compared to controls. Asian populations are noted to have a higher risk, emphasizing the need for close monitoring. To manage hyperkalemia, evidence-based protocols suggested starting finerenone with potassium level below 4.8mEq/L, discontinuing if potassium level exceed 5.5mEq/L. Strategies include dietary potassium restriction, potassium binders, and frequent monitoring. While these managements help mitigate risks, real-word challenges call for further evidence to refine practical guidelines. Finerenone emerges as a promising therapy for DKD but requires careful management to prevent hyperkalemia, ensuring optimal patient outcomes.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"22 2","pages":"29-32"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Renal Safety of Protocol-based 11.7% Hypertonic Saline Infusion Compared with 20% Mannitol in Patients with Elevated Intracranial Pressure: A Study Protocol for a Randomized Clinical Trial.","authors":"Sunggyul Lim, Yongjin Yi","doi":"10.5049/EBP.2024.22.2.33","DOIUrl":"https://doi.org/10.5049/EBP.2024.22.2.33","url":null,"abstract":"<p><strong>Background: </strong>Elevated intracranial pressure (ICP) is a potentially life-threatening condition requiring prompt intervention. While both mannitol and hypertonic saline (HTS) are commonly used hyperosmotic agents for treating elevated ICP, there is insufficient evidence comparing their renal safety profiles and overall effectiveness. This study protocol outlines a pragmatic randomized trial to compare protocol-based 11.7% HTS with 20% mannitol in patients with elevated ICP, focusing particularly on renal outcomes and treatment efficacy.</p><p><strong>Methods: </strong>This single-center, pragmatic randomized trial will enroll 116 intensive care unit patients with elevated ICP. Participants will be randomly assigned to receive either 11.7% HTS or 20% mannitol following a schedule-based randomization approach, with HTS administration during odd-numbered months and mannitol during even-numbered months. The study will regularly monitor serum electrolytes, osmolarity, and renal function, with brain CT evaluations conducted on days 3 and 7. Comprehensive clinical assessments, including neurological evaluations and laboratory tests, will be performed at specified intervals throughout the study period.</p><p><strong>Measured outcomes: </strong>Primary outcomes include the incidence of acute kidney injury within 7 days according to KDIGO guidelines, requirement for mechanical ventilation, development of pulmonary edema, and significant fluid retention. Secondary outcomes encompass ICU and hospital length of stay, 30- and 90-day mortality rates, and neurological outcomes assessed by Glasgow Coma Scale scores at days 7 and 30. The study hypothesizes that protocol-based HTS administration will demonstrate a lower incidence of acute kidney injury and related complications while maintaining comparable efficacy in managing elevated ICP.</p><p><strong>Conclusion: </strong>This study aims to provide definitive evidence regarding the relative efficacy and safety profiles of HTS compared to mannitol in managing elevated ICP. The findings will help establish clearer clinical guidelines for selecting appropriate hyperosmotic agents, potentially improving patient care outcomes and reducing treatment-related complications. This research will address a significant gap in current clinical knowledge and practice by focusing on treatment efficacy and renal safety considerations in patients with elevated ICP.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"22 2","pages":"33-39"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Recurrent Renal Infarction Following Transient Resolution: Evidence From Serial Computed Tomography.","authors":"In Hong Choi, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim, Hong Sang Choi","doi":"10.5049/EBP.2024.22.1.16","DOIUrl":"10.5049/EBP.2024.22.1.16","url":null,"abstract":"<p><p>Although renal infarction (RI) is not a rare disease, its outcomes have not been well-documented. Furthermore, transient resolution and recurrence of RI have not been captured through imaging. We report a case of idiopathic RI that recurred within a short period following transient resolution, as demonstrated by serial computed tomography (CT). A 53-year-old man diagnosed with RI was transferred to the emergency room. An abdominal CT scan at the local hospital revealed a segmental wedge-shaped perfusion defect in the left kidney and a focal thrombotic filling defect in the anterior segmental branch of the left renal artery. Since his left flank pain improved, another CT scan was performed again 6 hours after the initial CT scan. A repeat CT scan showed that the thrombus in the renal artery remained, but the perfusion defect had spontaneously resolved. We initiated anticoagulant therapy using unfractionated heparin. On the sixth day of hospitalization, the left flank pain recurred, prompting another CT scan. The follow-up CT scan confirmed that RI had recurred in the same area as before. We continued anticoagulant therapy and switched to warfarin. After treatment, his symptoms improved, and he was discharged. RI can recur at any time, even after it has spontaneously resolved, as evidenced by our case. Therefore, it is crucial to closely monitor patients who experience resolution of RI for any recurrence of symptoms, and repeat radiological evaluation should be performed even within a short period.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"22 1","pages":"16-20"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Fludrocortisone for Hyperkalemia in Chronic Kidney Disease Not Yet on Dialysis.","authors":"Eun Kyoung Lee, Won Seok Yang","doi":"10.5049/EBP.2024.22.1.8","DOIUrl":"10.5049/EBP.2024.22.1.8","url":null,"abstract":"<p><strong>Background: </strong>Hyperkalemia is a frequent and potentially lethal complication of chronic kidney disease (CKD). We retrospectively examined the potassium-lowering effect of oral fludrocortisone and its adverse effects in hyperkalemic CKD patients not yet on dialysis.</p><p><strong>Methods: </strong>Thirty-three patients (23 men and 10 women, ages 69±14 years) were included. To control hyperkalemia at the outpatient clinic, twenty-one patients (Group 1) received fludrocortisone (0.05-0.1 mg/day) without changes in angiotensin II receptor blockers (ARBs) and calcium polystyrene sulfonate (CPS), while twelve patients (Group 2) were treated with fludrocortisone in addition to stopping ARBs and/or adding low-dose CPS.</p><p><strong>Results: </strong>Fludrocortisone was administered for a median of 169 days (interquartile range, 47-445). At the first follow-up after fludrocortisone administration, serum potassium dropped from 6.14±0.32 mEq/L to 4.52±1.06 mEq/L (p<0.001) in Group 1 and from 6.37±0.35 mEq/L to 4.08±0.74 mEq/L (p<0.01) in Group 2. Ten patients in Group 1 and five patients in Group 2 measured serum potassium levels at four outpatient visits before and after fludrocortisone administration, respectively. The frequency of serum potassium ≥6.0 mEq/L decreased from 19/40 (48%) to 2/40 (5%) (p<0.001) in Group 1 and from 11/20 (55%) to 0/20 (0%) (p<0.001) in Group 2. Eleven patients experienced sodium retention-related problems after fludrocortisone administration: 7 with worsening leg edema, 2 with pleural effusions, and 2 with pulmonary edema.</p><p><strong>Conclusion: </strong>In pre-dialysis CKD patients, fludrocortisone at low doses effectively reduced serum potassium levels; however, sodium retention was a common adverse effect.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"22 1","pages":"8-15"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Renal Denervation Effective in Treating Resistant Hypertension?","authors":"Ji Hye Kim, Soon Kil Kwon","doi":"10.5049/EBP.2024.22.1.1","DOIUrl":"10.5049/EBP.2024.22.1.1","url":null,"abstract":"<p><p>Resistant hypertension is diagnosed in patients whose blood pressure target is unmet despite the use of three or more antihypertensive medications. Systemic sympathetic hyperactivation is associated with the development of resistant hypertension. As the kidney is largely pervasive of the sympathetic nervous system renal denervation procedure was developed to control blood pressure by attenuating the renal and systemic sympathetic hyperactivity. Renal denervation is a minimally invasive procedure that uses radiofrequency or ultrasound energy waves to reduce the activity of the renal artery nerves. Previous clinical trials have shown conflicting results regarding the efficacy of the procedure. Symplicity HTN-1 and -2 trials showed effective blood pressure lowering results in the renal denervation group with a good safety profile. However, the Symplicity HTN-3 trial showed no difference in blood pressure lowering effect between the renal denervation and control Sham procedure groups. Notwithstanding, some recent clinical trials with Sham control and meta-analysis showed clinical benefits of renal denervation. Other clinical benefits of renal denervation include glucose control, cardiovascular protective effect, reduction of obstructive sleep apnea, and neuralgia control. A subset of patients with satisfactory blood pressure control response to the procedure may experience improved glucose control due to the overall reduced sympathetic activity and insulin resistance. Sympathetic activity control after renal denervation has cardioprotective effects, especially for those with arrhythmia and left ventricular hypertrophy. Also, renal denervation could be helpful in renalorigin pain control. Renal denervation is an effective, safe, non-invasive procedure with many clinical benefits beyond blood pressure control. Further development in the procedure technique and selection of target patients are needed for wider clinical use of renal denervation in resistant hypertension.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"22 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Among Post-hemodialysis Blood Pressure, Nocturnal Hypertension, and Cardiovascular Risk Factors.","authors":"Hyunjeong Cho, Soon Kil Kwon, Seung Woo Lee, Yu Mi Yang, Hye Young Kim, Sun Moon Kim, Tae-Young Heo, Chang Hwan Seong, Kyeong Rok Kim","doi":"10.5049/EBP.2023.21.2.53","DOIUrl":"10.5049/EBP.2023.21.2.53","url":null,"abstract":"<p><strong>Background: </strong>Most hemodialysis (HD) patients suffer from hypertension and have a heightened cardiovascular risk. While blood pressure (BP) control is essential to end-stage kidney disease (ESKD) patients, overly stringent control can lead to intradialytic hypotension (IDH). This study aimed to examine BP variations during and after HD to determine whether these variations correlate with IDH risk.</p><p><strong>Methods: </strong>BP measurements during dialysis were taken from 28 ESKD patients, and ambulatory BP monitoring was applied post-dialysis. Laboratory parameters and risk factors, including diabetes, coronary disease, and LV mass index, were compared between IDH and non-IDH groups using an independent t-test.</p><p><strong>Results: </strong>Of the 28 patients with an average age of 57.4 years, 16 (57.1%) had diabetes, 5 (17.9%) had coronary artery disease, and 1 (3.6%) had cerebrovascular disease. The mean systolic blood pressure (SBP) during and post-HD was 142.26 mmHg and 156.05 mmHg, respectively (p=0.0003). Similarly, the mean diastolic blood pressure (DBP) also demonstrated a significant increase, from 74.59 mmHg during HD to 86.82 mmHg post-HD (p<0.0001). Patients with IDH exhibited a more substantial SBP difference (delta SBP, 36.38 vs. 15.07 mmHg, p=0.0033; age-adjusted OR=1.58, p=0.0168) and a lower post-dialysis BUN level (12.75 vs. 18.77 mg/dL, p=0.0015; age-adjusted OR=0.76, p=0.0242). No significant variations were observed in daytime and nocturnal BP between the IDH and non-IDH groups.</p><p><strong>Conclusion: </strong>Hemodialysis patients exhibited a marked increase in post-dialysis BP and lacked a nocturnal BP dip, suggesting augmented cardiovascular risks. This highlights the importance of more stringent BP control after hemodialysis.</p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"21 2","pages":"53-60"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}